# A jurisdiction desk with a commercial name and no commercial function > About This Desk — Buy Canadian Peptides — What Buy Canadian Peptides is: an independent literature digest on Research Peptide Fundamentals research peptides and the jurisdictions that categorise them differently. What it publishes, how it is assembled, and what it refuses to answer. **COLOPHON / EDITORIAL STANCE** What this site is, how each page is assembled, and the specific questions it declines to answer even though the domain name invites them. ## What this site is Buy Canadian Peptides is an independent reading desk covering four compounds — BPC-157, NAD+, semaglutide and tirzepatide — through a single lens: how the research on them is conducted and how regulators in different countries categorise the results. The name is a search phrase, and the site treats it as a subject heading rather than an offer. That distinction is load-bearing. Nothing here is for sale. No seller, pharmacy, clinic, compounder or laboratory is named or recommended, in Canada or anywhere else. No route for obtaining a substance in one country while living in another is described, and no border procedure is described either. The personal legality of moving a medicine across a national border is a legal question with a country-specific answer, and a literature digest has no standing to give one. What the site does instead is answer the question hiding underneath the phrase: why the same molecule carries a different legal status depending on which country is asked, and what that divergence does and does not tell a reader about the science. ## How a page is assembled Each compound page is composed from an already-audited body of literature for that compound rather than from an ad-hoc search. The citation list is fixed and numbered before the pages are written, and it is checked against that source material — which is why the bracketed numbers are stable and why no study appears in the text that is missing from the references page. Four editorial rules govern the writing. First, every quantitative claim carries a citation. Percentages, participant counts, hazard ratios, confidence intervals and durations all trace to a numbered source. Second, community-reported effects are labelled as anecdotal, not clinical evidence, kept visibly separate from trial findings, and never attached to an amount. Third, amounts appear only as descriptions of what a cited trial administered under supervision, never as a suggestion of what anyone might take. Fourth — and this one is specific to this desk — where a documented caution has no citable paper behind it in the audited material, it is printed without a bracket rather than with a borrowed one. An unbracketed caution means the concern is real and documented, and that this site cannot point at the study. Silently attaching the nearest available citation would be the easier move and a dishonest one. ## The jurisdictional stance, stated plainly This site describes the *structure* of regulatory divergence, not the current contents of any national register. The regulatory facts it does state — an FDA approval history, a 2023 compounding decision, a contested supplement definition, a World Anti-Doping Agency listing — are the ones carried in the audited source material behind each compound, and they are dated by it. Where no audited source exists, nothing is asserted. That is why these pages describe how Health Canada and every other national regulator *works in principle* while declining to summarise what any of them has currently decided. The reason is not squeamishness. Regulatory positions move, sometimes repeatedly within a couple of years, and a page that summarised one today would mislead a reader who found it in eighteen months. The structural account — a regulator rules on the applications filed with it, indication by indication, on its own timetable, reading the same trials as everyone else — does not go stale, and it is the part that actually changes how a reader interprets what they find. Two errors follow from ignoring it, and this site exists largely to name them. Approval somewhere is not evidence that a compound is safe for a particular person. Absence from a country's list is not evidence that a compound failed. Both mistakes are made constantly, and both come from reading a legal document as though it were a scientific one. ## Where this desk stops Several kinds of question sit outside what this site can honestly answer, and it is fairer to say so here than to hedge on every page. It cannot say what any compound will do for a particular person. Trials describe populations; a hazard ratio or a mean percentage change is a statement about a group, not a prediction about an individual reader. It cannot advise on amounts, schedules, combinations or cycling, and it does not publish that material even where a community consensus exists — a consensus is not evidence. It cannot verify what is inside any container. That limitation is worth taking seriously here, because unverified identity and purity are documented concerns for more than one compound on this desk. It cannot give legal advice about importation, personal possession or cross-border movement of any substance, in Canada or anywhere else. That is a question for a lawyer in the relevant jurisdiction, not for a research digest. And it stops where the literature stops. Where a compound has no validated human pharmacokinetics, the absence is reported rather than filled in with mechanism-flavoured speculation. Where a claim comes from cell culture or a rodent model, the species is named. Anyone weighing a decision about their own health needs a licensed clinician who can see their history; this desk exists for the step before that conversation. --- Buy Canadian Peptides is a citation-indexed reading desk on how different countries categorise the same molecules — it sells nothing, names no seller in any jurisdiction, and treats a gap between two regulators as a fact to explain rather than an offer to make.